Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination anti-human epidermal growth factor receptor 2 (anti-HER2) cancer therapy using mucin 1 (MUC1) peptides and hemotherapeutics

Combination anti-human epidermal growth factor receptor 2 (anti-HER2) cancer therapy using mucin 1 (MUC1) peptides and hemotherapeutics

US Patent 9789156 · Granted Oct 17, 2017

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Antibodies against the MUC1-c/extracellular domain (MUC1-C/ECD)2025
Antibodies against the MUC1-c/extracellular domain (MUC1-C/ECD)2025
Polymeric nanoparticles providing nucleic acids encoding TNF-α2022
Polymeric nanoparticles providing nucleic acids encoding TNF-α2022
Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)2021
Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)2021
Compositions and methods of treating cancer2021
Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)2020
Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)2020
Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)2018
Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)2018
Compositions and methods for treating cancer2017